glp 1 news today GLP-1 receptor agonists show promise in treating substance use disorders 🚨 BIG NEWS FOR MEDICARE

A medical provider must submit a prescription and prior authorization request, and the beneficiary must meet CMS clinical criteria

How should I take semaglutide GLP-1 during the first week

Fracture Risk Data from GLP1 Trials Several cardiovascular outcomes trials (CVOTs) have collected fracture data as secondary outcomes: Trials involving semaglutide and dulaglutide generally report fracture rates similar to placebo A few studies suggest a potential increase in non-vertebral fractures, though findings are inconsistent and often not statistically significant One important confounder is weight loss, which itself can lead to bone loss

Furthermore, in the EMPA-REG OUTCOME trial, empagliflozin reduced the risk of both pump failure and sudden deaths (46)

The information provided here is for educational purposes only and should not be taken as medical advice